Navigation Links
BioNeutral Group Achieves EPA Approval for Its Ygiene™ Disinfectant
Date:2/28/2011

NEWARK, N.J., Feb. 28, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced that it has received  approval and registration from the Environmental Protection Agency (EPA) in response to the Company's regulatory application for its Ygiene206.

In order to obtain regulatory approval for its hospital and industrial grade line of products to be used as high level disinfectant and sterilants, in August 2010, following several years of research and development under the direction of BioNeutral Chief Scientist Dr. Andrew Kielbania, PhD, and in collaboration with Dr. Philip Tierno, PhD, Chairman of its scientific advisory board, BioNeutral submitted an extensive EPA application along with the required independent GLP laboratory testing results.

After an intensive six month review of the nearly 1,500 page document, the EPA has granted its approval and registration (Reg No: 81242-1) for BioNeutral's Ygiene™ -206. 

This regulatory approval represents the addition of a significant new weapon being deployed in the ongoing effort to combat hospital acquired infections (HAIs). HAIs account for a high number of illnesses each year, resulting in what could otherwise be avoidable fatalities. Coupled with appropriate infection control programs, Ygiene™ is expected to  help reduce infections thereby not only potentially saving lives, but also redirecting scarce healthcare resources to overall improved medical care.

As an industrial grade antimicrobial, Ygiene also has applications in homeland security, as well as the hospitality, transportation and mold remediation sectors, to name just a few critical uses.

"The EPA's approval of BioNeutral's Ygiene disinfectant is very welcome news," said Dr. Philip Tierno, Jr., PhD, Director of Clinical Microbiology & Immunology at New York University Langone Medical Center and Clinical Professor of Microbiology & Pathology at New York University School of Medicine. "Ygiene™ will now give hospitals a far more powerful, yet much safer alternative to bleach, and to fight the ever increasing array of super-bugs in their environment."

"We are all extremely pleased," stated Dr. Andy Kielbania, Chief Scientist at BioNeutral Group, "This EPA approval is a milestone in the validation of our Ygiene™ technology and all of the various product lines it encompasses. We are now extremely well positioned to proceed with vigor in making both of our complementary platforms Ogiene™ and Ygiene™ products available to all."

"The EPA's approval of our antimicrobial technology comes at an extremely fortuitous time in the Company's development as we gain positive momentum first in Kentucky, under the direction of our services division CEO Frank Battafarano, and then beyond," said Stephen J. Browand Chairman, President and CEO of BioNeutral Group, Inc. "Having new and innovative tools for reducing and eliminating hospital acquired infections is more important than ever and we are proud to be contributing to this effort in such a meaningful way. BioNeutral is committed to ensuring that our game changing products get into the hands of the people and institutions that can bring about a much needed positive change to healthcare systems in this country and abroad."

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene™ and Ogiene™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace.  BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been approved by the EPA for sale in the United States and has previously  been approved for sale in Germany and it is also  permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.  

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393

Follow us on Twitter: http://twitter.com/bioneutralgroup

Forward-Looking Statements

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene -206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and will soon be available for sale in the United States.


'/>"/>
SOURCE BioNeutral Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc.
2. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
3. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
4. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
5. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
6. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
7. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
8. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
9. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
10. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
11. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins Privis ... Member for t4 Leadership Development & Consulting. He has spent his career focusing ... physician leadership development, servant leadership, data driven process improvement, and supportive technology. These ...
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... ... but not without risk to health and safety. By learning and implementing best ... eliminated. , In this webinar, attendees will gain a better understanding of ...
(Date:8/21/2017)... ... ... Five chefs from local senior assisted living homes will serve Mediterranean-inspired gourmet ... be able to vote for their favorite Chef among the following: , GREECE, Chef ... Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice Tea , ITALY, Chef Gabriel ...
(Date:8/21/2017)... ... , ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse ... Board of Trustees for a three-year term beginning January 1, 2018. , The ... that are committed to the improvement of health in their communities. Founded in 1898, ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA Solutions, LC ... has assisted multiple clients in successfully passing audits such as Office of Civil ... (AICPA SOC Level 2), and State Data Use Agreement Audits. , HIPAA ...
Breaking Medicine News(10 mins):